Ezgi Biltekin

Dr. Ezgi Biltekin

Biomedical Engineering, University of Houston, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EBEzgi Biltekin
Ezgi Biltekin
NKNermin Kahraman
Nermin Kahraman
OGOgun Ali Gul
Ogun Ali Gul
Metin AkayMetin Akay
Metin Akay
Metin AkayMetin Akay
Metin Akay
BOBulent ozpolat
Bulent ozpolat
Glioblastoma multiforme (GBM) is an aggressive and molecularly heterogeneous brain cancer with a poor prognosis. Despite advancements in standard-of-care therapies, including surgery, radiotherapy, and temozolomide (TMZ), the median survival remains approximately 15 months, with a 5-year survival rate of less than 10%. We and others have demonstrated that FOXM1 is a critical oncogenic driver of GBM cell proliferation. However, the role of FOXM1 and its interaction with other oncogenic signaling pathways in GBM remains incompletely understood. In this study, we identified FOXM1, AXL, and eEF2K as highly upregulated oncogenes in GBM patient tumors. We demonstrated, for the first time, that FOXM1 directly interacts with AXL and eEF2K, regulating their expression and promoting GBM cell proliferation, migration, and invasion. Knockdown of these genes disrupted cell proliferation, spheroid formation, migration, and invasion, and induced apoptosis and ferroptosis. Additionally, inhibiting the FOXM1–AXL/eEF2K signaling axis sensitized GBM cells to TMZ, further enhancing apoptotic and ferroptotic responses. These findings highlight the critical role of the FOXM1–AXL/eEF2K signaling pathway in GBM progression and suggest that targeting this axis may offer a novel multitargeted therapeutic strategy in GBM.

Verified
Journal Article
Open access
PDF file
MMMegan Mendieta
Megan Mendieta
MEHRDAD BANDEGIMEHRDAD BANDEGI
MEHRDAD BANDEGI
EBEzgi Biltekin
Ezgi Biltekin
Metin AkayMetin Akay
Metin Akay
BOBulent ozpolat
Bulent ozpolat
Metin AkayMetin Akay
Metin Akay
Glioblastoma Multiforme (GBM) is one of the most common brain tumors and is associated with aggressive tumor characteristics and extremely poor patient survival. The median survival time for GBM patients is around 12–15 months. Temozolomide (TMZ) is a key chemotherapeutic drug used in the treatment of GBM. However, at least 50% of GBM patients do not respond to TMZ, necessitating the identification of novel therapeutic strategies sensitizing patients to TMZ. In this study, we aimed to investigate the effects of two different tumor suppressor microRNAs (miR-329 and miR-449b) on cell proliferation and migration of GBM cells, and their potential for sensitizing GBM cells to TMZ. Our findings show that MiR-329/449b treatments suppressed spheroid formation and migration of GBM (LN229 and U87) cells. When miR treatments were combined with Temozolomide (TMZ), we also observed that they synergistically enhanced the suppressive effects of TMZ and inhibited the activity of clinically significant NF-KB and Src/FAK signaling pathways, making the combination therapy a viable option to treat GBM, with greater impact on patient survival.

30 March 2026 in IEEE Open Journal of Engineering in Medicine and Biology
Verified
Journal Article
Open access
MEHRDAD BANDEGIMEHRDAD BANDEGI
MEHRDAD BANDEGI
EBEzgi Biltekin
Ezgi Biltekin
Metin AkayMetin Akay
Metin Akay
BOBulent Ozpolat
Bulent Ozpolat
Metin AkayMetin Akay
Metin Akay
Colorectal cancer (CRC) ranks third in incidence among all malignancies and is highly lethal in advanced stages. Combination chemotherapy regimens based on 5-fluorouracil (5-FU) remain the mainstay of colorectal cancer treatment alongside surgical resection. Even though new treatment modalities are emerging, many are either ineffective against KRAS-mutant tumors or prone to therapy resistance. Therefore, there is a critical need for new targeted therapies that may overcome the KRAS-driven chemoresistance and enhance the effect of chemotherapy. MicroRNAs can modulate several oncogenic pathways at once and can strengthen chemotherapy. In this study, we identified miR-873 as a potential chemosensitizer that modulates KRAS/MAPK signaling in CRC. We found that KRAS is overexpressed in metastatic versus primary tissues and in a large CRC patient cohort (n = 1,061), high KRAS expression was associated with worse overall survival (HR = 1.27; 95% CI, 1.04–1.56; log-rank p = 0.018). In vitro inhibition of KRAS by siRNA reduced clonogenic growth (HCT116, p = 0.0023; RKO, p = 0.0018) and invasion (p ≤ 0.0001). In silico prediction (TargetScan/miRWalk) analyses showed a conserved binding site between miR-873 and KRAS 3′UTR. Consistent with this prediction, miR-873 mimic transfection reduced KRAS protein expression and phenocopied KRAS knockdown by suppressing colony formation (p ≤ 0.0021) and invasion (p ≤ 0.0001) in KRAS-mutant HCT116 and KRAS-wild-type RKO cells. Dose-matrix screening and SynergyFinder+ analysis revealed synergistic inhibition of spheroid viability with miR-873 + 5-FU, including a low-dose pair (25 nM miR-873 + 12.5 μM 5-FU) showing positive synergy across ZIP/HSA/Bliss/Loewe models. In a poly(ethylene glycol)diacrylate(PEGDA) microwell 3D platform that generates uniform, size-controlled CRC spheroids, this combination produced the strongest suppression of spheroid expansion (day-5/day-3 area: HCT116, 0.61 ± 0.18 vs control, 2.08 ± 0.49; RKO, 0.66 ± 0.04 vs control, 2.08 ± 0.31) and reduced the live-cell fraction to ∼41% in both lines. Moreover, western blot analysis showed decreased KRAS and MAPK pathway activity (reduced p-ERK and context-dependent p-MEK), reduced Cyclin D1, and increased apoptotic readouts (cleaved PARP and a Bax/Bcl-2 shift). Together, these results position miR-873 treatment as a potential targeting approach to suppress KRAS/MAPK signaling and sensitize CRC to 5-FU and validate our PEGDA microwell 3D platform as a practical, translational testbed for miRNA–chemotherapy combinations.

21 April 2025 in Cancer Research
Verified
Journal Article
Closed access
NKNermin Kahraman
Nermin Kahraman
EBEzgi Biltekin
Ezgi Biltekin
OGOgun Ali Gul
Ogun Ali Gul
GKGoknur Kara
Goknur Kara
IFIzabela Fokt
Izabela Fokt
BOBulent Ozpolat
Bulent Ozpolat
Colorectal cancer (CRC) is the third most commonly diagnosed cancer with 1.9 million new cases and the second leading cause of cancer-related deaths, with 935, 000 deaths reported in 2023. Despite advances in therapy, the 5-year survival rate for metastatic CRC remains as low as 14%, emphasizing the need for novel treatment strategies. Previously, we have validated that Eukaryotic elongation factor 2 kinase (eEF2K) is an atypical alfa kinase as a potential molecular target that is commonly expressed in highly aggressive solid cancers such as triple-negative breast cancer, pancreatic, ovarian, and lung cancers and demonstrated that it acts as a key player in the survival, proliferation, invasion, and tumor growth of cancer cells and promoting cell. In this study, we investigated the role of eEF2K in colon cancer tumorigenesis and progression and its potential as a therapeutic target using a novel eEF2K small molecule inhibitor and siRNA-based knockdown studies. We found that eEF2K expression is highly expressed in CRC cell lines and eEF2K is associated with shorter patient survival and poor prognostic marker in CRC patients (NCI-TCGA patient database), inhibition of eEF2K in various CRC cell lines (HCT116, RKO, COLO320, and with different genetic alterations leads to suppression on cell proliferation, migration, and invasion. Western blot analysis confirmed that treatment with the siRNA and the eEF2K inhibitor reduced the activity of clinically significant signaling molecules including Src, FAK, and Cyclin D1 which are crucial for tumor growth and progression. In vivo, targeting of eEF2K by eEF2K siRNA encapsulated in iron oxide nanoparticles (IONPS) and our novel water soluble small-molecule eEF2K inhibitor suppressed CRC tumor growth of HTC116 and RKO tumors (flank) CRC tumor models in nude mice, with no observed toxicity. Analysis of tumor tissues by immunohistochemistry showed significant inhibition of the Ki-67 proliferation marker and induction of apoptosis by TUNEL staining. Our study provides the first evidence that eEF2K is a clinically significant potential molecular target and contributes to tumorigenesis and progression of CRC. Its effective inhibition is safe and can suppress tumor growth in preclinical CRC models. These promising results lay the foundation for further developing eEF2K-targeted therapies, offering a potential new approach for treating CRC. Citation Format: Nermin Kahraman, Ezgi Biltekin, Ogun Ali Gul, Goknur Kara, Izabela Fokt, M. Akay Yasemin, Waldemar Priebe, Metin Akay, Bulent Ozpolat. Inhibition of Eukaryotic elongation factor 2 kinase (eEF2K) disrupts key processes in colorectal cancer progression and tumor growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6953.

4 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
EBEzgi Biltekin
Ezgi Biltekin
SDSayra Dilmac
Sayra Dilmac
NKNermin Kahraman
Nermin Kahraman
OGOgun Ali Gul
Ogun Ali Gul
Metin AkayMetin Akay
Metin Akay
BOBulent ozpolat
Bulent ozpolat
Glioblastoma multiforme (GBM) is defined by rapid progression, high invasiveness, and a poor prognosis, with a median survival of only ≅13 months despite current treatments. Its marked genetic heterogeneity, high mutational burden, and cancer stem cell population make GBM exceptionally difficult to treat, highlighting the urgent need for more effective, multitargeted therapies. Non-coding RNAs, particularly tumor suppressor microRNAs (miRNAs), have gained attention for suppressing key oncogenic processes that drive tumorigenesis, metastasis, and drug resistance, positioning them as promising tools for targeting multiple oncogenic pathways. We recently found that FOXM1/AXL-eEF2K collaboratively drive GBM cell proliferation, survival, and invasion through the formation of a signaling hub complex. In this study, we employed miRNA prediction algorithms to identify a specific miRNA, in vitro functional assays and in vivo GBM flank model to target GBM tumorigenesis by distrupting the FOXM1/AXL-eEF2K signaling hub. Our results indicated that FOXM1, AXL, and eEF2K are overexpressed in GBM patient tumors. To target the FOXM1/AXL-eEF2K signaling hub, we identified miR-449b-5p, miR-329-3p, and miR-518c as potential co-inhibitors of FOXM1/AXL-eEF2K and suppressors of cell proliferation, migration–invasion, and spheroid formation. Furthermore, the combination of miR-449b-5p, miR-329-3p, and miR-518c treatments with temozolomide led to synergistic enhancements in cell proliferation suppression and the induction of apoptosis and ferroptosis. More importantly, in vivo miR-329-3p treatment led to remarkable suppression of GBM tumor xenografts. These findings indicate that miR-329-3p-based tumor suppressor therapy may offer a multitargeted approach for GBM treatment.

1 November 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
EBEzgi Biltekin
Ezgi Biltekin
NKNermin Kahraman
Nermin Kahraman
OGOgun Ali Gul
Ogun Ali Gul
SDSayra Dilmac
Sayra Dilmac
YAYasemin M Akay
Yasemin M Akay
BOBulent Ozpolat
Bulent Ozpolat
Glioblastoma multiforme (GBM) is a WHO grade IV glioma, that is characterized by its aggressive growth, high invasiveness, and poor clinical outcomes. Despite the current standard of care treatments -surgical resection, radiotherapy, and first-line chemotherapy with temozolomide- the median survival remains only 12–17 months, with a 5-year survival rate of approximately 7%. GBM tumors defined by significant molecular heterogeneity, elevated mutational burden, and presence of therapy-resistant cancer stem cells. Thus, there is an urgent need for innovative, multi-targeted therapeutic strategies. Recent research highlighted the potential of non-coding RNAs, particularly microRNAs, to regulate multiple oncogenic pathways simultaneously. Our analyses of the Rembrandt patient dataset identified three significantly overexpressed key oncogenic signaling molecules (eEF2K, AXL, and FOXM1) in GBM patient tumors and in GBM cell lines. To therapeutically target these drivers, we utilized miRNA-Target gene prediction algorithms and identified three candidate miRNAs with predicted direct binding affinity. We demonstrated, for the first time, that miR-329-5p, miR-449-5p and miR-518c negatively regulate eEF2K, AXL, FOXM1 oncogenes and effectively downregulate their expression. Furthermore, we performed colony formation, wound healing(scratch), invasion(transwell) and 3D spheroid formation assay to evaluate the effects of the candidate miRNAs on cellular proliferation, metastatic potential, and stemness characteristics of GBM. Simultaneously or combined targeting of eEF2K, AXL, FOXM1 oncogenic molecules by each of the miRNAs(miR-329-5p, miR-449-5p, or miR-518c) led to suppression of GBM cell proliferation, migration, invasion, spheroid formation and induced both apoptosis and ferroptosis. Importantly, the combination of these miRNAs with temozolomide produced synergistic anti-proliferative effects in vitro. Moreover, in vivo once a week systemic treatment with miR-329-3p(0.15 mg/kg) incorporated in single lipid nanoparticle significantly suppressed eEF2K, AXL, FOXM1 expression and tumor growth in LN229 GBM xenograft tumor model in mice. These findings support the therapeutic potential of miRNA-based interventions as a multi-targeting strategy, either as monotherapy or in combination with current chemotherapeutics, for more effective management of glioblastoma.